Surface display of glycosylated Tyrosinase related protein-2 (TRP-2) tumour antigen on Lactococcus lactis

BMC Biotechnology

Volumn 15, Issue 1, 2015, Pages

  Kalyanasundram, Jeevanathan ^a   Chia, Suet Lin ^a   Song, Adelene Ai Lian ^a   Raha, Abdul Rahim ^a   Young, Howard A ^b   Yusoff, Khatijah ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Lactococcus lactis; Lysin motif; Surface display; Tyrosinase related protein 2

Indexed keywords

AFFINITY CHROMATOGRAPHY; ANTIGENS; CELL MEMBRANES; CELLS; CYTOLOGY; DISPLAY DEVICES; EPITOPES; LACTIC ACID; MAMMALS; PURIFICATION; VACCINES;

CELL SURFACE PRESENTATION; CHINESE HAMSTER OVARY; LACTOCOCCUS LACTIS; LYSIN MOTIF; PROKARYOTIC EXPRESSION SYSTEM; SURFACE DISPLAY SYSTEM; SURFACE DISPLAYS; TYROSINASE RELATED PROTEIN-2;

PROTEINS;

DOPACHROME TAUTOMERASE; GLYCOPROTEIN; TUMOR ANTIGEN; DOPACHROME ISOMERASE; ISOMERASE; PRIMER DNA;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; BACTERIAL CELL WALL; CARBOXY TERMINAL SEQUENCE; CELL SURFACE DISPLAY; CHO CELL LINE; CONTROLLED STUDY; IMMUNOFLUORESCENCE MICROSCOPY; LACTOCOCCUS LACTIS; NONHUMAN; PROTEIN GLYCOSYLATION; PROTEIN MOTIF; PROTEIN PURIFICATION; ANIMAL; ANTIGEN PRESENTATION; CELL WALL; CRICETULUS; FLUORESCENCE MICROSCOPY; GENETICS; HAMSTER; METABOLISM; MOUSE; PHYSIOLOGY; PLASMID;

ANIMALS; ANTIGEN PRESENTATION; CELL WALL; CHO CELLS; CHROMATOGRAPHY, AFFINITY; CRICETINAE; CRICETULUS; DNA PRIMERS; INTRAMOLECULAR OXIDOREDUCTASES; LACTOCOCCUS LACTIS; MICE; MICROSCOPY, FLUORESCENCE; PLASMIDS;

EID: 84952672746     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/s12896-015-0231-z     Document Type: Article

References (48)

1. Ramasamy R, Yasawardena S, Zomer A, Venema G, Kok J, Leenhouts K. Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. Vaccine. 2006;18(24):3900-8.
2. Lim SH, Jahanshiri F, Rahim RA, Sekawi Z, Yusoff K. Surface display of respiratory syncytial virus glycoproteins in Lactococcus lactis NZ9000. Lett Appl Microbiol. 2010;51(6):658-64.
3. Cortes-Perez NG, Azevedo V, Alcocer-González JM, Rodriguez-Padilla C, Tamez-Guerra RS, Corthier G, et al. Cell-surface display of E7 antigen from human papillomavirus type-16 in Lactococcus lactis and in Lactobacillus plantarum using a new cell-wall anchor from lactobacilli. J Drug Target. 2005;13(2):89-98.
4. Westerlund B, Korhonen TK. Bacterial proteins binding to the mammalian extracellular matrix. Mol Microbiol. 1993;9:687-94.
5. Perdigón G, Fuller R, Raya R. Lactic Acid Bacteria and their Effect on the Immune System. Curr Issues Intest Microbiol. 2001;2(1):27-42.
6. Pontes DS, de Azevedo MSP, Chatel JM, Langella P, Azevedo V, Miyoshi A. Lactococcus lactis as live vector: Heterologous protein production and DNA delivery systems. Protein Expr Purif. 2011;79(2):165-75.
7. Li X, Xing Y, Guo L, Lv X, Song H, Xi T. Oral immunization with recombinant Lactococcus lactis delivering a multi-epitope antigen CTB-UE attenuates Helicobacter pylori infection in mice. Pathog Dis. 2014;72(1):78-86. doi: 10.1111/2049-632X.12173.
8. Morello E, Bermudez-Humaran LG, Llull D, Sole V, Miraglio N, Langella P, et al. Lactococcus lactis, an Efficient Cell Factory for Recombination Protein Production and Secretion. J Mol Microbiol Biotechnol. 2008;14:48-58.
9. Raha AR, Varma NRS, Yusoff K, Ross E, Foo HL. Cell surface display system for Lactococcus lactis: a novel development for oral vaccine. Appl Microbiol Biotechnol. 2005;68:75-81.
10. Bahey-El-Din M, Gahan CG, Griffin BT. Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins. Current Gene Ther. 2010;10:34-4.
11. Pejawar-Gaddy S, Finn OJ. Cancer vaccines: Accomplisments and Challenges. Critical Reviews in Oncology. Hematology. 2008;93-102.
12. Kelkar SM, Shenoy MS, Kaklij GS. Antitumour activity of lactic acid bacteria on a solid fibrosarcoma, sarcoma-180 and Ehrlich ascites carcinoma. Cancer Lett. 1988;42:73-7.
13. Satonaka K, Ohashi K, Nohmi T, Yamamoto T, Abe S, Uchida K, et al. Prophylactic effect of Enterococcus faecalis FK-23 preparation on experimental candidiasis in mice. Microbiol Immunol. 1996;40:217-22.
14. Rafter J. Lactic acid bacteria and cancer: mechanistic perspective. Br J Nutr Suppl. 2002;Suppl 1:S89-94.
15. Matsuzaki T, Chin J. Modulating immune responses with probiotic bacteria. Immunol Cell Biol. 2000;78(1):67-73.
16. Ribelles P, Benbouziane B, Langella P, Suárez JE, Bermúdez-Humarán LG. Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. Appl Microbiol Biotechnol. 2013;97(3):1395.
17. Fredriksen L, Mathiesen G, Sioud M, Vincent GHE. Cell Wall Anchoring of the 37-Kilodalton Oncofetal Antigen by Lactobacillus plantarum for Mucosal Cancer Vaccine Delivery. Appl Environ Microbiol. 2010;76(21):7359-62.
18. Yamano T, Kaneda Y, Sharon H, Hiramatsu HS, Hoon DS. Enhancement of Immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol Ther. 2005;13:194-202.
19. InSug O, Blaszczyk-Thurin M, Shen C, Ertl HC. A DNA vaccine expressing tyrosinase-related protein 2 induces T-cell-mediated protection against mouse glioblastoma. Cancer Gene Ther. 2003;10:678-88.
20. Liu G, Akasaki Y, Khong HT, Wheeler CJ, Das A, Black KL, et al. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene. 2005;24:5226-34.
21. Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D, Morris J, Ritter E, et al. Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity. PLoS ONE. 2010;5(9):e12670. doi: 10.1371/journal.pone.0012670.
22. Xu G, Smith T, Grey F, Hill AB. Cytomegalovirus-based cancer vaccines expressing TRP-2 induced rejection of melanoma in mice. Biochem Biophys Res Commun. 2013;437(2):287-91.
23. Zhu X, Cai J, Huang J, Jiang X, Ren D. The treatment and prevention of mouse melanoma with an oral DNA vaccine carried by attenuated Salmonella typhimurium. J Immunother. 2010;33(5):453-60.
24. Bruhn KW, Craft N, Nguyen BD, Yip J, Miller JF. Characterization of anti-self CD8 T-cell responses stimulated by recombinant Listeria monocytogenes expressing the melanoma antigen TRP-2. Vaccine. 2005;23(33):4263-72.
25. Kajikawa A, Masuda K, Mitsunori K, Shizunobu I. Adjuvant Effects for Oral Immunization Provided by Recombinant Lactobacillus casei Secreting Biologically Active Murine Interleukin-1. Clin Vaccine Immunol. 2010;17:43-8.
26. Mercenier A, Müller-Alouf H, Grangette C. Lactic acid bacteria as live vaccines. Curr Issues Mol Biol. 2000;2:17-25.
27. Steitz J, Brück J, Steinbrink K, Enk A, Knop J, Tüting T. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer. 2000;86(1):89-94.
28. Lindholm A, Smeds A, Palva A. Receptor binding domain of Escherichia coli F18 fimbrial adhesin FedF can be both efficiently secreted and surface displayed in a functional form in Lactococcus lactis. Appl Environ Microbiol. 2004;70(4):2061-71.
29. Kwaks TH, Otte AP. Employing epigenetics to augment the expression of therapeutic proteins in mammalian cells. Trends Biotechnol. 2006;3:137-42.
30. Varma NRS, Toosa H, Foo HL, Alitheen NBM, Nor Shamsudin M, Arbab AS, et al. Display of the viral epitopes on Lactococcus lactis: a model for food grade vaccine against EV71. Biotechnol Res Int. 2013;2013:431315.
31. Moeini H, Rahim RA, Omar AR, Shafee N, Yusoff K. Lactobacillus acidophilus as a live vehicle for oral immunization against chicken anemia virus. Appl Microbiol Biotechnol. 2011;90:77-88.
32. Aroca P, Garcia-Borron JC, Solano F, Lozano JA. Regulation of mammalian melanogenesis. I: Partial purification and characterization of a dopachrome converting factor: dopachrome tautomerase. Biochim Biophys Acta. 1990;1035(3):266-75.
33. Terzaghi BE, Sandine WE. Improved medium for lactic streptococci and their bacteriophages. Appl Microbiol. 1975;29:807-13.
34. Pozzi G, Contorni M, Oggioni MR, Manganelli R, Tommasino M, Cavalieri F, et al. Delivery and expression of a heterologous antigen on the surface of streptococci. Infect Immun. 1992;60(5):1902-7.
35. Robinson K, Chamberlain LM, Schofield KM, Wells JM, Le Page RW. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat Biotechnol. 1997;15(7):653-7.
36. Piard JC, Hautefort I, Fischetti VA, Ehrlich SD, Fons M, Gruss A. Cell wall anchoring of the Streptococcus pyogenes M6 protein in various lactic acid bacteria. J Bacteriol. 1997;179(9):3068-72.
37. Steidler L, Robinson K, Chamberlain L, KM S e, Remaut E, Le Page RW, et al. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect Immun. 1998;66(7):3183-9.
38. Steen A, Buist G, Leenhouts KJ, El Khattabi M, Grijpstra F, Zomer AL, et al. Cell wall attachment of a widely distributed peptidoglycan binding domain is hindered by cell wall constituents. J Biol Chem. 2003;278:23874-81.
39. Tarahomjoo S, Katakura Y, Satoh E, Shioya S. Expression of C-terminal repeat region of peptidoglycan hydrolase of Lactococcus lactis IL1403 in methylotrophic yeast Pichia pastoris. J Biosci Bioeng. 2008;105(2):134-9.
40. Bosma T, Kanninga R, Neef J, Audouy SA, van Roosmalen ML, Steen A, et al. Novel surface display system for proteins on non-genetically modified gram-positive bacteria. Appl Environ Microbiol. 2006;72(1):880-9.
41. Ostankovitch M, Altrich-Vanlith M, Robila V, Engelhard VH. N-glycosylation enhances presentation of a MHC class I-restricted epitope from tyrosinase. J Immunol. 2009;182:4830-5.
42. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol. 1997;15:553-7.
43. Romanos M. Advances in the use of Pichia pastoris for high-level gene expression. Curr Opin Biotechnol. 1995;6:527-33.
44. Stratton-Thomas JR, Min HY, Kaufman SE, Chiu CY, Mullenbach GT, Rosenberg S. Yeast expression and phagemid display of the human urokinase plasminogen activator epidermal growth factor-like domain. Protein Eng. 1995;8(5):463-70.
45. Davila E, Kennedy R, Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003;63(12):3281-8.
46. Miconnet I, Coste I, Beermann F, Haeuw JF, Cerottini JC, Bonnefoy JY, et al. Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction. J Immunol. 2001;166(7):4612-9.
47. Tsukamoto K, Jackson IJ, Urabe K, Montague PM, Hearing VJ. A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase. EMBO J. 1992;11(2):519-26.
48. Vavricka CJ, Ray KW, Christensen BM, Li J. Purification and N-glycosylation analysis of melanoma antigen dopachrome tautomerase. Protein J. 2010;29(3):204-1.